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Chromatin is traditionally viewed as a nuclear entity that regulates gene expression and 
silencing1-3. However, we recently discovered the presence of cytoplasmic chromatin 
fragments that pinch off from intact nuclei of primary cells during senescence4,5, a form of 
terminal cell cycle arrest associated with pro-inflammatory responses6.  The functional 
significance of chromatin in the cytoplasm is unclear.  Here we show that cytoplasmic 
chromatin activates the innate immunity cytosolic DNA sensing cGAS-STING pathway, 
leading to both short-term inflammation to restrain activated oncogene and chronic 
inflammation that associates with tissue destruction and cancer.  The cytoplasmic 
chromatin-cGAS-STING pathway promotes the senescence-associated secretory phenotype 
(SASP) in primary human cells and in mice.  Mice deficient in STING show impaired 
immuno-surveillance of oncogenic RAS and reduced tissue inflammation upon ionizing 
radiation.  Furthermore, this pathway is activated in cancer cells, and correlates with pro-
inflammatory gene expression in human cancers.  Overall, our findings indicate that 
genomic DNA serves as a reservoir to initiate a pro-inflammatory pathway in the 
cytoplasm in senescence and cancer.  Targeting the cytoplasmic chromatin-mediated 
pathway may hold promise in treating inflammation-related disorders.   
 
Chromatin undergoes global reorganization and degeneration during cellular 
senescence1,5,7-10, a stress response that associates with human diseases including cancer and 
aging6.  A hallmark of senescence is loss of the nuclear lamina protein Lamin B17,11,12, leading to 
compromised integrity of the nuclear envelope4,5.  Concomitantly, nuclear membrane blebs that 
contain chromatin fragments appear in senescent cells, which eventually partition into the 
cytoplasm to become cytoplasmic chromatin fragments (CCF)4,5. CCF contain genomic DNA, 
γH2AX, and heterochromatin markers H3K9me3 and H3K27me3, but lack certain euchromatin 
markers, such as H3K9ac, indicating that CCF are derived from transcriptionally repressed 
heterochromatin regions and involve the DNA damage response (DDR)4,5.  The transport of 
genomic DNA to the cytoplasm is unusual, as nuclear DNA is regarded as a stable entity that 
encodes organismal genetic information.  Whether cytoplasmic chromatin is associated with any 
biological function is unclear.   
Senescence of multiple primary cell types, induced by oncogenic HRasV12, DNA 
damage, or replication exhaustion, exhibits CCF that stain with DAPI, γH2AX, and H3K27me3 
(Fig. 1a and Extended Data Fig. 1a-c).  Cytoplasmic DNA, typically a consequence of pathogen 
infection, can be recognized by the cytosolic DNA sensor cGAS, which produces a second 
messenger cyclic GMP-AMP (cGAMP) that activates STING13,14. The cGAS-STING pathway 
plays essential roles in restraining microbial infection and in triggering inflammation15-17.  cGAS 
in proliferating cells displays a diffuse pattern, but coalesces into sharp and bright puncta that 
colocalize with CCF in senescent cells (Fig. 1a and Extended Data Fig. 1c-f).  cGAS activation, 
measured by the production of cGAMP, was detected in cells transfected with 90-mer double-
strand DNA (dsDNA90), and, importantly, in senescent cells triggered by various means (Fig. 1b 
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and Extended Data Fig. 1g).  Moreover, STING shows hallmarks of activation in senescent cells, 
including formation of homo-dimers (Fig. 1c and Extended Data Fig. 1h) and redistribution into 
aggregates (Extended Data Fig. 1i-j).  STING activation correlates with induction of CCF and 
expression of the pro-inflammatory gene IL1α (Fig. 1c and Extended Data Fig. 1k).  An 
alternative source of cytoplasmic chromatin in proliferating cells could be chromosome 
segregation errors, including micronuclei18,19.  Together, these results indicate that cytoplasmic 
chromatin in senescence signals to the cGAS-STING pathway. 
Activation of cGAS-STING leads to two downstream pathways: type I interferon through 
IRF3, and pro-inflammatory responses through NFκB16.  Senescence associates with robust 
induction of CCF and pro-inflammatory genes, but not interferon genes (Extended Data Fig. 2a-
e).  The failure to induce interferon could be caused by activated p38 MAPK in senescence20, as 
p38 inhibits STING-mediated interferon induction21.  p38 inhibitor SB203580 potentiates 
interferon β expression in senescence (Extended Data Fig. 2f).  Furthermore, the cultured media 
derived from senescence, particularly IL1α, suppress dsDNA90-induced interferon β (Extended 
Data Fig. 2g-i). The suppression of interferon in senescence is consistent with the observation 
that chronic interferon response can lead to activation of immune checkpoints22.  
The secretion of pro-inflammatory cytokines is a key feature of senescence, referred to as 
the SASP6.  SASP is able to recruit immune cells, modulate their activity, and alter the tissue 
microenvironment6.  The mechanisms that activate SASP involve a series of poorly understood 
events that are connected to the DDR and NFκB23,24. We hypothesized that the CCF-cGAS-
STING pathway promotes the SASP program.   
First, we stably reduced cGAS or STING expression (Fig. 2a and Extended Data Fig. 3a), 
and then induced senescence (Fig. 2b).  While disruption of cGAS or STING does not affect 
several markers of senescence (Fig. 2c and Extended Data Fig. 3b), the activation of key SASP 
factors is greatly compromised (Fig. 2c and Extended Data Fig. 3c-d).  We subsequently 
performed RNA-sequencing in control and cGAS-deficient cells undergoing DNA-damage-
induced senescence, using two independent biological replicates.  Gene Ontology (GO) analysis 
of the top downregulated genes in cGAS-deficient cells revealed significant enrichment of the 
SASP program (Fig. 2d and Supplementary Table 1, and examples shown in Fig. 2e and 
Extended Data Fig. 3e).  The global reduction of SASP is also presented by a heatmap (Extended 
Data Fig. 3f).  The role of cGAS-STING in mediating the SASP was confirmed at the secreted 
protein level in the conditioned media (Fig. 2f and Extended Data Fig. 3g-h).   
We then asked whether cGAS-STING regulates SASP in established senescence.  
Following senescence establishment, STING or cGAS was inactivated, which does not revert 
senescence, but significantly reduces the expression of SASP genes (Extended Data Fig. 3i).  By 
contrast, disruption of IFI16, a disputed cytosolic DNA sensor25, does not suppress SASP 
(Extended Data Fig. 3j-k). Taken together, these results indicate that cGAS-STING is required 
for both induction and maintenance of the SASP program. 
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We examined the DDR and NFκB pathways that are involved in SASP23,24.  Suppression 
of STING or cGAS has little effect on p-ATM S1981, p-p53 S15, γH2AX, senescence-associated 
heterochromatin foci (SAHF), or CCF in senescent cells (Fig. 2g and Extended Data Fig. 4a-b), 
but greatly compromises the activation of NFκB, as judged by phosphorylation of NFκB 
p65/RelA subunit on Serine 536 (Fig. 2g), nuclear translocation of the p65 subunit and its 
association with promoter regions of pro-inflammatory genes (Extended Data Fig. 4c-d).  These 
data connect the cGAS-STING pathway with the NFκB-mediated SASP program.  
We manipulated CCF and investigated the consequences.  The generation of CCF is a 
consequence of compromised nuclear lamina integrity, mediated by loss of Lamin B14,5.  
Downregulation of Lamin B1 leads to elevated CCF while overexpression of Lamin B1 impairs 
the generation of CCF4,5.  Overexpression of Lamin B1 has little effect on the induction of 
γH2AX, p-ATM S1981, and p-p53 S15, but significantly impairs the induction of CCF, STING 
dimer, p65 phosphorylation, and the SASP gene expression (Extended Data Fig. 4e-h).  In 
contrast to reducing CCF, exogenous delivery of cytoplasmic DNA or chromatin fragments 
induces cGAS-dependent activation of SASP genes (Extended Data Fig. 4i-k).  Taken together, 
these data demonstrate that the CCF-cGAS-STING pathway promotes the SASP program in 
primary human cells.    
We subsequently employed wild-type and Sting-null mice15, and exposed these mice to  
sub-lethal dose of ionizing irradiation (IR) that induces DNA damage, senescence, and the SASP 
program12,23.  This procedure stimulates cGAMP and cytoplasmic chromatin in hepatocytes 
(Extended Data Fig. 5a-b).  While IR promotes γH2AX accumulation in the liver of both wild-
type and the null mice, the induction of IL1α is significantly attenuated in the null mice (Fig. 3a 
and Extended Data Fig. 5c).  Three months after IR, wild-type mice, but not the null mice, 
exhibit massive hair greying (Fig. 3b).  Hence, STING mediates DNA damage-induced SASP 
and tissue inflammation in vivo.   
We also investigated Ras-induced senescence in vivo.  A vector with a Sleeping Beauty 
transposon that co-expresses NRasV12 and luciferase, together with a transposase construct, was 
delivered through hydrodynamic injection (Fig. 3c-d), leading to specific and stable expression 
of NRasV12 in hepatocytes.  This procedure induces hepatocyte senescence, SASP and 
inflammation, leading to immune-mediated clearance of pre-malignant hepatocytes10,26,27. 
NRasV12, but not the NRasV12/D38A mutant, induces inflammation (Fig. 3e top left and 
Extended Data Fig. 6a), and formation of cytoplasmic chromatin in hepatocytes (Extended Data 
Fig. 6b).  While senescence is comparable between wild-type and the null liver (Extended Data 
Fig. 6c-e), the null liver shows attenuated inflammation (Fig. 3e top right).  Furthermore, the null 
liver possesses deficient induction of SASP genes and accumulation of immune cell markers (Fig. 
3f and Extended Data Fig. 6f).  The clearance of NRas-hepatocytes was subsequently examined.  
While wild-type mice show significantly reduced numbers of NRasV12-expressing cells from 
day 6 to day 12, the null mice fail to do so (Fig. 3e).  Using the luciferase reporter co-expressed 
with NRasV12 (Fig. 3c), we found that wild-type mice show gradual reduction of luciferase 
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luminescence in the liver, whereas the luciferase activity persists in the null mice (Fig. 3g).  
Impaired clearance of NRasV12-hepatocytes can lead to malignancies26.  Eight months following 
the injection, intrahepatic tumors positive for NRas were observed in the null mice but not in the 
wild-type mice (Fig. 3h and Extended Data Fig. 6g).  The role of STING in this model was 
confirmed by re-expression of STING in the null liver, which results in restoration of cytokine 
expression, inflammation, and immune-mediated clearance (Extended Data Fig. 7a-e).  Taken 
together, these results demonstrate that STING in vivo is essential for Ras-induced SASP and 
immuno-surveillance.  
While senescence and short-term inflammation is a potent barrier to tumorigenesis, 
persistent inflammation is associated with tissue damage, and in established cancers, is linked to 
tumor growth and metastasis6.  Since cancers frequently contain extra-nuclear chromatin18,19 and 
depend on NFκB for inflammation24, we investigated the role of cytoplasmic chromatin in pro-
inflammatory responses in cells that evade senescence (either bypassing initiation of senescence 
or by escape after induction of senescence) and in human cancers in general. 
To study senescence evasion, we first induced senescence of IMR90 cells by HRasV12, 
which were then either left untreated (termed as OIS’ed), or were immortalized by stable 
expression of SV40 large T antigen and hTERT (termed as OIS-evaded) (Fig. 4a-b).  Although 
the OIS-evaded cells show loss of SAHF, they retain an elevated DDR, cytoplasmic chromatin 
that strongly colocalize with cGAS (Fig. 4c-d, and Extended Data Fig. 8a), and the expression of 
pro-inflammatory genes, mediated by the cGAS-STING pathway (Fig. 4e-f, and Extended Data 
Fig. 8b-c).  These observations suggest that in transformed cells, the cytoplasmic chromatin-
mediated pathway remains activated, and hence prompted us to investigate cytoplasmic 
chromatin in human cancers.   
Although cancer cells may arise from various mechanisms, we found that cytoplasmic 
chromatin is present in multiple cancer cell lines (Extended Data Fig. 8d-e), consistent with 
studies showing nucleus-to-cytoplasm transport of nuclear DNA in cancer cells18,19.  We 
discovered that cytoplasmic chromatin in the investigated cancer cells stains positive for DAPI 
and γH2AX, colocalizes with cGAS, and is negatively regulated by Lamin B1 (Extended Data 
Fig. 8d-f).  Moreover, the expression of pro-inflammatory genes is regulated by cGAS, STING, 
and Lamin B1 (Extended Data Fig. 8g and Supplementary Table 2), similar to that of senescent 
cells.  Furthermore, analyses of ten breast cancer cell lines revealed that cytoplasmic chromatin 
associates with the expression of pro-inflammatory genes (Extended Data Fig. 8h and 
Supplementary Table 3).   
To robustly examine the connection between cytoplasmic chromatin-mediated pathway 
and pro-inflammatory gene expression in cancers at a larger scale, we exploited the cancer cell 
line encyclopedia (CCLE) that contains RNA-sequencing datasets for over 1,000 cell lines28.  
Cancer cells with the lowest ¼ and highest ¼ of STING expression were grouped, and the 
expression of key pro-inflammatory genes were compared between the STING-low and STING-
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high subsets (Fig. 4g).  This analysis revealed that higher STING expression is linked to 
significantly higher expression of pro-inflammatory genes, while interferon genes and the house-
keeping gene GAPDH do not follow this pattern (Fig. 4g top and Extended Data Fig. 9a top).  A 
similar trend is also observed with cGAS (Extended Data Fig. 9b).  In contrast, Lamin B1, but 
not Lamin A/C, shows strong negative association with the pro-inflammatory genes (Fig. 4g 
bottom and Extended Data Fig. 9a, c), consistent with the observations that Lamin B1, but not 
Lamin A/C, regulates cytoplasmic chromatin-mediated pathway4,5.  The association of pro-
inflammatory gene expression is specific to the cytosolic DNA sensing pathway, because MAVS, 
a protein involved in cytosolic RNA sensing pathway, does not show this association (Extended 
Data Fig. 9d).    
Furthermore, we exploited the RNA-sequencing database of human cancers from the 
cancer genome atlas (TCGA), and again found that STING is significantly linked to the 
expression of pro-inflammatory genes in multiple cancers, including but not limited to pancreatic 
cancer, melanoma, prostate cancer, and breast cancer, while MAVS does not follow this pattern 
(Extended Data Fig. 10a-d and Supplementary Table 4).  
Collectively, these data suggest that the cytoplasmic chromatin-cGAS-STING pathway is 
involved in expression of pro-inflammatory genes in cancer cells that evade senescence and in 
broad scenarios of human cancers in general.   
In conclusion, this study establishes a functional role of cytoplasmic chromatin in 
mediating inflammation in senescence and cancer.  This view suggests that genomic DNA not 
only carries central genetic information, but can also serve as a cytoplasmic “danger signal” to 
alarm the immune system in coping with aberrant cellular activities.  While clearly a short-term 
advantage in promoting immuno-surveillance of malignancies, this machinery may have a long-
term destructive potential in creating genomic instability and in mediating tissue damage.  While 
this manuscript was in revision, two related findings appeared and collectively support an 
essential role of the cytoplasmic chromatin-cGAS-STING pathway in mediating the SASP29,30.  
We envision that the cytoplasmic chromatin phenomenon may be involved in many biological 
processes beyond the current investigation.  
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Figure legend 
Figure 1. CCF activates cGAS-STING pathway in cellular senescence.  a, Primary IMR90 
stably expressing Flag-tagged cGAS were treated as indicated, and imaged under a confocal 
microscopy.  CCF are indicated by arrows. Scale bar: 10 µm.  b, Detection of cGAMP by nano-
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LC-MS.  (Left) Cell metabolites were fractionated by HPLC, and the presence of cGAMP at the 
m/z of 675.11 (z=1+) was measured.  (Right) Tandem mass (MS2) spectra of the detected 
cGAMP.  c, IMR90 cell lysates were subjected to immunoblotting.  STING blots were 
performed under non-reducing condition.  * indicates STING dimer.  SE, short exposure; LE, 
long exposure.   
 
Figure 2. CCF-cGAS-STING pathway promotes the SASP.  a, IMR90 as indicated were 
analyzed by immunoblotting.  b, Schematic illustration of experimental design. c, IMR90 were 
analyzed by immunoblotting for senescence and SASP markers.  d, GO analysis from RNA-seq, 
showing the most significant GO terms and the number of genes.  e, Track views of IL1 gene 
loci.  f, Cytokine-array analyses of secreted factors in etoposide-induced senescent IMR90.    g, 
IMR90 cell lysates were analyzed by immunoblotting.  Quantification of p-p65 normalized to 
total p65 is shown.  * p<0.01, compared to Eto NTC condition, n=3 independent experiments, 
one-way ANOVA coupled with Tukey’s post hoc test.  
 
Figure 3. STING mediates SASP in mice.  a, One-week post IR, liver was analyzed by 
immunohistochemistry and quantified; n=8 mice.  Scale bar: 20 µm.  b, Representative images of 
mice three-month post IR. c-d, Schematic illustration of constructs and experimental design.  e, 
Immunohistochemistry analyses of liver.  Clusters of immune cells are highlighted.  Scale bar: 
100 µm.  n=8 mice, *p<0.005, **p<0.0001.  f, Liver was harvested on day 6 and analyzed by 
RT-qPCR. n=10 mice for WT; n=13 mice for null.  g, Luminescent imaging of mice. n=3 mice, * 
p<0.05, ** p<0.01. h,  Representative images of liver tumors. Graphs showing mean values with 
s.e.m.; unpaired two-tailed Student’s t-test.   
 
Fig. 4. Cytoplasmic chromatin mediates pro-inflammatory responses in senescence evasion 
and cancer.  a, Scheme of experimental design.  b, SA-β-Gal images of the three cell types.  c, 
Confocal microscopy analyses of OIS-evaded cells.  Scale bar: 10 µm.  d, Quantification of cells 
for parameters as indicated.  Results are the average values of four different fields with over 200 
cells.  Error bars: s.d.; *p<0.0001; NS: non-significant; unpaired two-tailed Student’s t-test.  e-f, 
Cells as indicated were analyzed by immunoblotting.  g, CCLE analyses of STING and Lamin 
B1 with inflammatory gene expression profiles.   
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Methods 
Cell culture and treatment 
Primary IMR90 and BJ fibroblasts were described previously and were authenticated by 
genome-wide sequencing analyses5,7.  The cells were cultured in DMEM supplemented with 10% 
fetal bovine serum (FBS), 100 units/ml penicillin, and 100 μg/ml streptomycin (Invitrogen), and 
were intermittently tested for mycoplasma.  The cells were cultured under physiological oxygen 
(3%), and were used within population doubling of 35, except for replicative senescence 
experiments.  For etoposide-induced senescence, IMR90 cells at ~60-70% confluency were 
treated with 100 uM etoposide for 48 h. The media were then replaced and cells were harvested 
at Day 7.  For BJ cells, 40 uM etoposide were added to the culture media throughout the 
treatment.  IMR90 stably expressing ER:HRas was described previously5. Senescence-associated 
β-galactosidase was performed as previously described5,31.  dsDNA90 was described elsewhere32, 
and transfected using lipofectamine 2000; transfected cells were harvested 1 day post 
transfection for analysis of interferon β and 4 days for pro-inflammatory cytokines. 
 
Mice experiments 
STING+/+ and STING-/- mice in C57BL/6 background were described elsewhere15.  Mice were 
fed ad libitum on a regular diet, and all procedures were approved and performed following 
institutional regulations and guidelines (University of Pennsylvania and University of Glasgow).  
Both sexes were included in the study.  Hydrodynamic tail vein injection was performed as 
previously described33.  Briefly, 20 ug of NRasV12/luciferase and 10 ug of transposase 
constructs were injected to mice that are 8 to 12-week-old in Ringer's solution that corresponds 
to 10% of the body weight (e.g., 2.0 ml for a 20 g mouse, but not over 2.5 ml if the mouse is 
more than 25 g) within 6 s.  Mouse Sting cDNA was purchased from Origene and was cloned 
into the NRas/IRES/luciferase vector.  All constructs were verified by DNA sequencing.  For in 
vivo luciferase imaging, luciferin was intraperitoneally injected to mice at 150 mg/kg body 
weight.  The mice were anesthetized using isoflurane and imaged under an IVIS Spectrum 
imager every minute for a duration of 15 min.  Images with peak signals were used for data 
analyses.  Identical parameters were used for longitudinal study and for comparisons between the 
two cohorts of mice.  For ionizing radiation, mice were subjected to a sub-lethal dose of 4 Gy 
irradiation, and were harvested 7 days post the procedure for IHC studies.  Presented images of 
mice post IR are representative of no less than five mice per condition.  Isolation of primary 
hepatocytes is described elsewhere33.   Liver tumor studies were performed following 
institutional regulations and guidelines (University of Pennsylvania, animal protocol #805175).  
A maximal loss of 20% of body weight is considered as an endpoint.  None of the experiments 
exceeded the limit.  Immunohistochemistry was performed using standard procedure at the 
institutional histology core facilities and was scored in a double-blinded manner.   
 
Reagents and antibodies 
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Etoposide, 4-hydroxytamoxifen, puromycin, and polybrene were purchased from Sigma. 
Hygromycin was from Gemini Bio Products, and luciferin was from PerkinElmer.  Recombinant 
human IL1α protein (used at 20 ng/ml) was from R&D Systems, and p38 MAPK inhibitor from 
Selleck Chemicals. 
The following antibodies were described previously: Flag, p16, Lamin B1, GAPDH, and GFP5.  
Other antibodies used include: γH2AX (Abcam #ab2893 and Cell Signaling Technology #9718), 
STING (Cell Signaling Technology #13647 and LSBio #LS-B7237), cGAS (Cell Signaling 
Technology #15102 and Santa Cruz Biotechnology #sc-245858), human IL1α (Abcam #ab9614), 
IL8 (Abcam #ab18672), p-ATM S1981 (Abcam #ab81292), p-p53 S15 (Cell Signaling 
Technology #9284), p-p65 S536 (Cell Signaling Technology #3033), p65 (Cell Signaling 
Technology 8242), NRas (Santa Cruz Biotechnology #sc-31), CD3 (Abcam #ab16669), Mac2 
(BioLegend #125401), mouse IL1α (R&D Systems #AF-400), p21 (#sc-471), and H3 (Active 
Motif #39763).  
 
Retrovirus and lentivirus 
Retroviral GFP, GFP-Lamin B1, WZL-HRasV12 constructs, and production of virus for stable 
expression was performed as previously described5.  Retroviral constructs (including LPC-
cGAS-Flag) were transfected to phoenix packaging cell line.  Lentiviral pLKO constructs were 
transfected with packaging plasmids to HEK293T cells. Viral supernatant was filtered through a 
0.45-μm filter, supplemented with 8 μg/ml polybrene, and mixed with trypsinized recipient cells.  
The infected cells were then selected with puromycin or hygromycin. 
 
pLKO-based shRNA was from Sigma.  The following shRNA were used:  
STING (TRCN0000163296: GCCCGGATTCGAACTTACAAT and TRCN0000161345: 
GTCCAGGACTTGACATCTTAA), cGAS (TRCN0000149984: 
CAACTACGACTAAAGCCATTT and TRCN0000128706: CGTGAAGATTTCTGCACCTAA), 
IFI16 (TRCN0000364688: GGAAACTCTGAAGATTGATAT and TRCN0000364735: 
CTGGATGTCATTGACGATAAT), and Lamin B1 (TRCN0000029269: 
CCAGGGAAGAACTGATGGAAA and TRCN0000029271: 
GCATGAGAATTGAGAGCCTTT).  
 
Immunoblotting 
Western blotting was described previously5, with slight modifications.  Cells were lysed in buffer 
containing 50 mM Tris pH 7.5, 0.5 mM EDTA, 150 mM NaCl, 1% NP40, 1% SDS, 
supplemented with 1:100 Halt Protease and phosphatase inhibitor cocktail (Thermo Scientific). 
The lysates were briefly sonicated, and supernatants were subjected to electrophoresis using 
NuPAGE Bis-Tris precast gels (Life Technologies).  For p-ATM S1981 blotting, cells were 
lysed in 20 mM Tris, pH 7.5, 137 mM NaCl, 1 mM MgCl2, 1 mM CaCl2, 1% NP-40, 10% 
glycerol, supplemented with 1:100 Halt protease and phosphatase inhibitor cocktail (Thermo 
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Scientific) and benzonase (Novagen) at 12.5 U/ml.  The lysates were rotated at 4 °C for 1 h, and 
supernatants were loaded.  For immunoblotting of STING dimer, reducing reagent was not added 
to the lysates before loading.  After transferring to nitrocellulose membrane, 5% milk in TBS 
supplemented with 0.1% Tween 20 (TBST) was used to block the membrane at room 
temperature for 1 h.  Primary antibodies were diluted in 5% BSA in TBST, and incubated at 4 °C 
overnight. The membrane was washed 3 times with TBST, each for 10 min, followed by 
incubation of HRP-conjugated secondary antibodies at room temperature for 1 h, in 5% 
milk/TBST.  The membrane was washed again 3 times, and imaged by films or by a GE 
Amersham Imager 600. 
 
Immunofluorescence and quantification 
Immunofluorescence was performed as described previously5.  Briefly, cells were fixed in 4% 
paraformaldehyde in PBS for 30 min at room temperature.  Cells were washed twice with PBS, 
and permeabilized with 0.5% Triton X-100 in PBS for 10 min. After washing two times, cells 
were blocked in 10% BSA in PBS for 1 h at room temperature.  Cells were then incubated with 
primary antibodies in 5% BSA in PBS supplemented with 0.1% Tween 20 (PBST) overnight at 
4 °C. The next day, the cells were washed four times with PBST, each for 10 min, followed by 
incubation with Alexa Fluor-conjugated secondary antibody (Life Technologies), in 5% 
BSA/PBST for 1 h at room temperature.  The cells were then washed four times in PBST, 
incubated with 1 μg/ml DAPI in PBS for 5 min, and washed twice with PBS. The slides were 
mounted with ProLong Gold (Life Technologies), and imaged with Leica TCS SP8 fluorescent 
confocal microscope.  Quantification of % positive cells of SAHF, p-ATM, IL8, γH2AX, and 
p65 was done under identical microscopy settings between samples.  Cells with over 5 visible 
spots at the expected location were considered positive. Over 200 cells from 4 randomly-selected 
fields were analyzed.  
 
RT-qPCR 
mRNA from cells or tissues were extracted with RNeasy Mini Kit (Qiagen), with a DNase I 
(Qiagen) digestion step to minimize genomic DNA contamination.  Reverse transcription (RT) 
was done using High-Capacity RNA-to-cDNA Kit (ThermoFisher), and then quantitative PCR 
(qPCR) was performed using the 7900HT Fast-Real-Time PCR platform (ABI).  Results were 
normalized to GAPDH for human cells.   
The following primers were used for RT-qPCR of human cells:  
IL1α: TGTAAGCTATGGCCCACTCCA, AGAGACACAGATTGATCCATGCA; 
IL1β: CTCTCTCCTTTCAGGGCCAA, GAGAGGCCTGGCTCAACAAA; 
IL6: CACCGGGAACGAAAGAGAAG, TCATAGCTGGGCTCCTGGAG; 
IL8: ACATGACTTCCAAGCTGGCC, CAGAAATCAGGAAGGCTGCC; 
MMP3: GGATGCCAGGAAAGGTTCTG, CCAGGTGTGGAGTTCCTGATGT; 
GAPDH: CAGCCTCAAGATCATCAGCA, TGTGGTCATGAGTCCTTCCA; 
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STING: ATATCTGCGGCTGATCCTGC, TTGTAAGTTCGAATCCGGGC; 
cGAS: GGCGGTTTTGGAGAAGTTGA, GCCGCCGTGGAGATATCAT; 
IFI16: CTACCCCAGGAACAGCGTCA, GGTTGTGCTGGCCTCTGAAG; 
p16: CCAACGCACCGAATAGTTACG, CCATCATCATGACCTGGATCG; 
Lamin B1: CTCTCGTCGCATGCTGACAG, TCCCTTATTTCCGCCATCTCT. 
 
For mouse liver NRas/luciferase related RT-qPCR, three pieces of liver from the same mouse 
were combined as one sample (n=1), and the mRNA and RT were performed as aforementioned.  
The results of SASP factors were normalized to the value of luciferase as an internal control for 
NRas abundance.   
 
The following primers were used for RT-qPCR of mouse tissues: 
IL1α: AGGAGAGCCGGGTGACAGTA, TCAGAATCTTCCCGTTGCTTG; 
IL1β: CCAAAAGATGAAGGGCTGCT, TCATCAGGACAGCCCAGGTC; 
IL8: CTGGTCCATGCTCCTGCTG, GGACGGACGAAGATGCCTAG; 
CXCL1: CAATGAGCTGCGCTGTCAGT, TTGAGGTGAATCCCAGCCAT; 
MMP3: TGGAGCTGATGCATAAGCCC, TGAAGCCACCAACATCAGGA; 
CD45: CGCGGTGTAAAACTCGTCAA, CCCCAAATCTGTCTGCACATT; 
CD3: CAAGAGCTGCCTCAGAAGCA, CGAGAAATCCTGGAGCACCA; 
B220: CGCGGTGTAAAACTCGTCAA, CCCCAAATCTGTCTGCACATT; 
CD68: TGGCGGTGGAATACAATGTG, TGAATGTCCACTGTGCTGCC; 
Klrd1: TCTGAATGCTGTGTTTGCCTG, ACAATTGCACTGATGCCCAA; 
Luciferase: CGCTGGAGAGCAACTGCATA, CCAGGAACCAGGGCGTATCT; 
GAPDH: GGAGCGAGACCCCACTAACA, ACATACTCAGCACCGGCCTC; 
18s: GTAACCCGTTGAACCCCATT, CCATCCAATCGGTAGTAGCG. 
 
 
Chromatin immunoprecipitation (ChIP) 
ChIP was described previously5 with slight modification.  Cells were crosslinked with 1% 
formaldehyde diluted in PBS for 5 min at room temperature.  After glycin quenching, the cell 
pellets were lysed in buffer containing 50 mM Tris, pH 7.4, 150 mM NaCl, 1% Triton, 0.1% 
SDS, supplemented with complete protease inhibitor cocktail (Thermo Scientific), and sonicated 
with a Covaris sonicator, resulting in chromatin fragments of 250 bp average size.  The 
supernatant was diluted 10 times with the above buffer without SDS, and subjected to 
immunoprecipitations with 1 ug of p65 antibody or control IgG conjugated with Dynabeads 
Protein A (Invitrogen) at 4 °C for overnight.  The beads were then washed 4 times with buffer 
containing 50 mM Tris, pH 7.4, 150 mM NaCl, 1% Triton, and 1 time with final wash buffer (50 
mM Tris, pH 8.0, 10 mM EDTA, 50 mM NaCl), followed by elution with incubation of elution 
buffer (final wash buffer plus 1% SDS) at 65 °C for 30 min with agitation in a thermomixer.  
The ChIP and input were then purified and used for qPCR analysis. The following primers were 
used for qPCR of gene promoter regions: 
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IL8: CCACCGGAAGGAACCATCT, GGCCAGCTTGGAAGTCATGT; 
IL6: CACCTGGAGACGCCTTGAAG, TGCCTGGCCATCCTCAAAT; 
MMP3: TGGATTTGCTGGTTCTTGAGG, TTTGTTCTATTCTGCCCATGAGG; 
β-actin: CTGGGTTTTATAGGGCGCC, AAGTTGCCTTTTATGGCTCGAG. 
 
 
RNA-sequencing 
RNA-seq was performed as previously described7,8 with modifications.  Total RNA was isolated 
from IMR90 cells using RNeasy kit (Qiagen) and 1 ug of RNA was used as input in the Scriptseq 
Complete kit (Epicentre).  Briefly, total RNA was ribo-depleted using a Ribozero magnetic 
protocol (Epicentre). The ribo-depleted RNA was then ethanol-precipitated, fragmented, and 
tagged at both ends for stranded library preparation, using the Scriptseq v2 library preparation 
protocol.  The PCR amplification step was used to index the libraries and multiplexed libraries 
were quantified by Bioanalyzer (Agilent) and qPCR (Kapa Biosystems).  The RNA-seq run was 
performed on the NextSeq 500 platform (Illumina). 
 
Single-ended, 75 bp reads were mildly trimmed using Trimmomatic (version 0.32) to remove 
leading or trailing nucleotides whose sequencing quality was below 3. Reads whose length fell 
below 30 bp after trimming were also removed from downstream analysis. STAR (version 2.3.0e) 
was used for mapping reads to reference genome (hg19), requiring a minimum alignment score 
of 10. The expression level of RefSeq genes was quantified using featureCounts (version 1.5.0) 
and normalized using DESeq2. 
 
Gene expression of RNA-seq data were compared in log2-CPM (i.e. log2 read per million 
mapped reads) as reported by DESeq2. The average log2-CPM values were used for biological 
replicates.  Genes with over three fold change in expression between etoposide-treated sh-NTC 
and sh-cGAS were uploaded to DAVID for GO analysis.  Genes contributed to the top four 
down-regulated GO terms were combined with known SASP genes34 for heatmap visualization, 
where expression of each gene was scaled to between 0 and 1 based on its minimum and 
maximum values in proliferating, etoposide-treated sh-NTC and sh-cGAS. SASP genes that are 
induced less than three-fold (comparing etoposide-treated sh-NTC and proliferating) and those 
that are not induced in IMR90 DNA damage conditions34 are not included for the heatmap.  
 
RNA-sequencing data were uploaded to GEO under accession number GSE99028. 
 
Secreted cytokine analysis 
For western and cytokine-array analysis of secreted cytokines, cells were cultured in serum-free 
media for 24 h. The cultured media were then collected, and the cell numbers were counted for 
normalization.  The media were filtered with a 0.45 µm PVDF filter (Millipore) to remove cells 
and debris.  The resulting supernatant was further concentrated with a 3kDa Amicon Ultra 0.5 
mL centrifugal filter (Millipore), and was subjected to immunoblotting of IL8 or cytokine-array 
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assay (RayBiotech, Human Cytokine Array C1) following manufacturer’s guidelines.  The 
intensities of array dots were quantified with Fiji and were normalized against the positive 
controls on the blots.  
Chromatin fragment extraction and transfection 
Extraction of chromatin fragments was described previously35 with modifications.  Briefly, 
proliferating IMR90 cells were incubated with hypotonic buffer (10 mM Tris, pH 7.4, 30 mM 
NaCl, 3 mM MgCl2, 0.1% NP40), supplemented with protease inhibitor cocktail, on ice for 10 
min.  The cells were then centrifuged at 300 g, 4 °C, for 3 min.  The supernatant was carefully 
removed, and the resulting pellets were incubated with benzonase buffer (50 mM Tris pH 7.5, 
300 mM NaCl, 0.5% NP40, 2.5 mM MgCl2) with protease inhibitor cocktail, supplemented with 
10 U of benzonase, on ice, for 30 min.  The product was centrifuged again at 300 g, 4 °C, for 3 
min, and benzonase was inactivated by addition of 15 mM EDTA. The resulting supernatant 
contains chromatin fragments and soluble nuclear proteins.  The product was then diluted 5 times 
with PBS.  As a control, buffer without benzonase was used, which yielded soluble nuclear 
proteins but no chromatin fragments.  The chromatin fragments or the control were transfected to 
proliferating IMR90 cells using lipofectamine 2000.  Successful transfection was confirmed by 
immunofluorescence with an H3 antibody and DAPI.  Transfected cells were harvested 4 days 
post transfection, and were analyzed by RT-qPCR for cytokine production.    
 
 
2’3’-cGAMP detection by LC-MS/MS 
cGAMP extraction was performed as reported by Chen et al36, with slight modifications.  IMR90 
cells were cultured in 10 cm dishes, and the culture media were removed and replaced with 2 ml 
80:20 methanol:water.  The dishes were incubated at -80 °C overnight, and cells were scraped, 
subjected to 2 vortex, freeze/thaw cycles in liquid nitrogen, and sonicated in a Bioruptor 
sonicator in ice water bath. The product was clarified by centrifugation at 21,000 g for 20 min at 
4 °C, and the supernatant was concentrated by a SpeedVac concentrator and subjected to sample 
clean-up and LC-MS analysis.  For mouse hepatocytes and liver, tissues were homogenized in 
80:18:2 methanol:water:acetic acid, and were processed similarly as afore-mentioned. The 
pellets from the centrifugation step were dissolved in 1% SDS followed by sonication, and the 
concentration of proteins were measured by Pierce™ BCA Protein Assay Kit, allowing 
normalization to total proteins.  
Dried supernatants were re-suspended in 50 μL 0.1% acetic acid and subjected to solid phase 
extraction.  Briefly, the bottom of a P200 pipette tip was sealed with a small disk of C18 material 
(Millipore). To the pipette tip, 200 μL of phenyl-hexyl resin (5 μm, 100 Å, Phenomenex) 
resuspended in acetonitrile was added.  A centrifuge adaptor was used to hold stage-tips in place 
in 1.5 ml microcentrifuge tubes. The resin was flushed with 50 μL of acetonitrile by slow 
centrifugation. The resin was then equilibrated with 50 μL of 0.1% acetic acid and samples were 
loaded onto the equilibrated resin. Samples were washed once with 0.1% acetic acid and eluted 
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into a clean microcentrifuge tube by flushing 50 μL of 20 % acetonitrile with 0.1 % formic acid 
twice. Samples were collected, dried in a SpeedVac concentrator and resuspended in 0.1 % 
formic acid for LC-MS analysis. 
LC-MS analysis was carried out using an EASY-nLC nano HPLC (Thermo Scientific) coupled 
to an Orbitrap Fusion mass spectrometer (Thermo Scientific), equipped with a nano-electrospray 
source. Ionization source parameters were optimized using a 2’3’- cGAMP standard (InvivoGen) 
and set to: positive mode; capillary temperature, 275 °C; spray voltage, 2.3kV. Analytes were 
separated on an in-house analytical column (150 µm ID, 370 mm length) packed with a phenyl-
hexyl resin 5 μm, 100 Å (Phenomenex).  The mobile phases were 0.1% (v/v) formic acid (A) and 
acetonitrile with 0.1% (v/v) formic acid (B).  Analytes were eluted using the following gradient: 
0 – 20% B in 20 min, 20 – 98% B in 5 min and maintained over 10 min at 600 nL/min.  The 
mass spectrometer was set to perform a full MS scan (300 – 700 m/z) in the Orbitrap with a 
resolution of 120,000 (at 200 m/z), followed by targeted MS/MS scans of the precursor ion of 
cGAMP  (m/z = 675.10 [M + H]1+). Fragment ions were scanned from 185 – 700 m/z.  All 
MS/MS scans were performed in the orbitrap mass analyzer (15,000 resolution) using HCD 
fragmentation (collision energy = 25), and an isolation window of 1.0 m/z. Maximum injection 
times of 50 and 100 ms were defined for  MS and MS/MS scans, respectively. AGC values were 
set to 5 x 105 for MS and 5 x 104 for MS/MS.  MS data were collected in profile mode and 
MS/MS data were collected in centroid mode. 
 
The Cancer Genome Atlas (TCGA) and Cancer Cell Line Encyclopedia (CCLE) analyses 
The results of TCGA were based upon data generated by the TCGA Research Network: 
http://cancergenome.nih.gov.  For TCGA analyses, RNA sequencing datasets were obtained 
from cBioportal (www.cbioportal.org).  For a given cancer type, tumor samples were ranked 
based on their targeted gene expression values, and were evenly divided into four groups 
accordingly. Statistical comparisons were then performed between the first group (samples with 
the lowest 25% expression) and the last group (samples with the highest 25% expression) for 
inflammatory genes or the house-keeping gene (GAPDH), as denoted.  Similarly, for analyses of 
the CCLE samples, RNA sequencing datasets were obtained from the Broad Institute data portal 
(www.portals.broadinstitute.org/ccle/home).  The samples were ranked as described above for 
TCGA samples, and likewise, comparisons were carried out between the first group and the last 
group for inflammatory genes or GAPDH. For box plots displayed in this study, the central 
rectangle spans a range from the first quartile to the third quartile (this range is also known as the 
interquartile range, IQR). A line inside the rectangle shows the median. Outliers were defined as 
data points that are either 1.5×IQR or more above the third quartile or 1.5×IQR or more below 
the first quartile.  If either type of outlier is present, the whisker on the appropriate side is taken 
to 1.5×IQR from the quartile rather than the maximum or minimum.  Outliers were not displayed 
in the box plots, but all data points were included in P-value calculations.  One-sided Wilcoxon 
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rank sum test were used to compute statistical significance.  P values less than 0.05 were 
considered significant.  
 
General statistical analyses 
Unpaired two-tailed Student’s t-test was used for comparison between two groups. One-way 
ANOVA coupled with Tukey’s post hoc test was used for comparisons over two groups.  All bar 
graphs show mean values with error bars (s.d. or s.e.m., as defined in figure legends), unless 
specified otherwise.  95% confidence intervals were used, and significance was considered when 
p value was less than 0.05. 
 
Data availability statement 
RNA-sequencing data were uploaded to GEO under accession number GSE99028.  The authors 
declare that the data that support the findings of this study are available within the article and 
Supplementary Information.  Related data are available from the authors upon reasonable request. 
No restriction on data availability applies. 
 
31 Debacq-Chainiaux, F., Erusalimsky, J. D., Campisi, J. & Toussaint, O. Protocols to detect 
senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent 
cells in culture and in vivo. Nat Protoc 4, 1798-1806, doi:10.1038/nprot.2009.191 
nprot.2009.191 [pii] (2009). 
32 Abe, T. et al. STING recognition of cytoplasmic DNA instigates cellular defense. Mol 
Cell 50, 5-15, doi:10.1016/j.molcel.2013.01.039 S1097-2765(13)00128-7 [pii] (2013). 
33 Wangensteen, K. J., Zhang, S., Greenbaum, L. E. & Kaestner, K. H. A genetic screen 
reveals Foxa3 and TNFR1 as key regulators of liver repopulation. Genes Dev 29, 904-
909, doi:10.1101/gad.258855.115 29/9/904 [pii] (2015). 
34 Freund, A., Orjalo, A. V., Desprez, P. Y. & Campisi, J. Inflammatory networks during 
cellular senescence: causes and consequences. Trends Mol Med 16, 238-246, 
doi:10.1016/j.molmed.2010.03.003 S1471-4914(10)00046-8 [pii] (2010). 
35 Rai, T. S. & Adams, P. D. ChIP-Sequencing to Map the Epigenome of Senescent Cells 
Using Benzonase Endonuclease. Methods Enzymol 574, 355-364, 
doi:10.1016/bs.mie.2016.01.021 S0076-6879(16)00066-5 [pii] (2016). 
36 Chen, Q. et al. Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP 
transfer. Nature 533, 493-498, doi:10.1038/nature18268 nature18268 [pii] (2016). 
 
Extended Data Figure legend 
Extended Data Figure 1. CCF-cGAS-STING activation in senescence.  a,  Confocal 
microscopy analyses of primary MEFs. CCF indicated by arrows.  b, Quantification of IMR90 
undergoing replicative senescence.  PD: population doubling.  c, Microscopy-based 
19 
 
quantification of parameters as indicated.  d-f, Confocal microscopy analyses of BJ (d), IMR90 
stained for endogenous cGAS (e), and mitotic IMR90 (f). g, cGAMP detection by nano-LC-MS.  
MS2 spectra were confirmed for cGAMP.  h, IMR90 were analyzed by immunoblotting.  STING 
blots were performed under non-reducing condition.  * indicates STING dimer.  i-j, Confocal 
microscopy images of STING in IMR90 (i) and BJ (j). k, Cells as in Fig. 1c were quantified 
under microscopy.  Bar graphs show mean values of four different fields with over 200 cells and 
s.d.  Scale bars: 10 µm.   
 
Extended Data Figure 2. Interferon genes are repressed in senescent human fibroblasts.  a-
b, ER:HRasV12 IMR90 were induced by OHT and quantified for CCF (a) or analyzed by RT-
qPCR (b). c-d, IMR90 were treated with etoposide and analyzed similarly as above. Results 
shown in b and d were from triplicate technical replicates, and were normalized to the untreated 
sample.  Bar graphs (a and c) show mean values of four different fields with over 200 cells and 
s.d. e, RNA-seq values of indicated genes.  n=3; error bars: s.d.  f, IMR90 were treated with a 
p38 inhibitor. *p<0.005, **p<0.0001, compared to DMSO.  g, Cultured media from proliferating 
or senescent IMR90 were administered to proliferating cells, followed by dsDNA90 transfection. 
*p<0.0001, compared to control media.  h, IMR90 were incubated with recombinant IL1α and 
transfected with dsDNA90. *p<0.01, **p<0.0001, compared to no-IL1α transfected groups.  f-h 
shows RT-qPCR analyses with mean values and s.d.; n=3; unpaired two-tailed Student’s t-test.  i, 
Schematic illustration of interferon repression in senescence.   
 
Extended Data Figure 3. CCF-cGAS-STING pathway activates the SASP.  a, Cells 
transfected with dsDNA90 were analyzed by RT-qPCR. b, Cells as in Fig. 2c were stained for 
SA-β-Gal and quantified.  c, IMR90 were analyzed by RT-qPCR. *p<0.0001, compared to sh-
NTC etoposide.  d, IMR90 were analyzed by immunoblotting.  e, Track views of indicated genes 
from RNA-seq. f, Heatmap representation of SASP genes. g, Cultured media were analyzed by 
IL8 immunoblotting.  h, Related to Fig. 2f, quantification of secreted cytokines. *p<0.001, 
**p<0.0001, comparing to sh-NTC.  i-j, RT-qPCR analyses of established senescent cells. 
*p<0.005, **p<0.0001, compared to +OHT sh-NTC. j, IFI16 does not regulate the SASP. k, 
IFI16 plays a regulatory but not essential role upon dsDNA90 transfection.  Bar graphs show 
mean values with s.d.; n=3; one-way ANOVA coupled with Tukey’s post hoc test for c and h; 
unpaired two-tailed Student’s t-test for i.  
 
Extended Data Figure 4. Role of CCF-cGAS-STING in SASP activation.  a-c, IMR90 were 
analyzed by confocal microscopy.  *p<0.005, compared to sh-NTC HRasV12.  d, p65 ChIP-
qPCR analyses. *p<0.05, **p<0.01, compared to sh-NTC.  e-h, IMR90 overexpressed with 
Lamin B1 were analyzed by immunofluorescence (e), immunoblotting (f-g), or RT-qPCR (h). 
20 
 
*p<0.01, **p<0.001.  i,  IMR90 were transfected with dsDNA90 and analyzed 4 days later for 
RT-qPCR. *p<0.0001.  j-k, IMR90 were transfected with chromatin fragments, stained for H3, 
quantified for CCF (j), and analyzed by RT-qPCR (k). *p<0.005, **p<0.0001, compared to sh-
NTC transfected.  Bar graphs for a-c, e, and j are the average values of four different fields with 
over 200 cells.  Error bars are s.d.;  n=3 unless noted; one-way ANOVA coupled with Tukey’s 
post hoc test (a-d); unpaired two-tailed Student’s t-test (e, g-k).  Scale bars: 10 µm.   
 
Extended Data Figure 5.  Characterization of IR in mouse liver.  a, Detection of cGAMP in 
IR hepatocytes by nano-LC-MS.  b, Control or IR hepatocytes of WT mice were isolated and 
stained as indicated.  Representative confocal images are shown.  CCF are indicated by arrows.  
Scale bar: 5 µm.  c, Related to Fig. 3a, IHC staining in no IR control liver.  
 
Extended Data Figure 6.  STING promotes Ras-induced SASP in the liver.  a, 
Immunohistochemistry of WT liver injected with NRasV12/D38A mutant.  b, Hepatocytes of 
injected WT mice were isolated on day 6 and stained.  CCF-positive hepatocytes were quantified.  
Results are average values of four different fields with over 200 cells; *p<0.001, compared to 
control and NRasV12/D38A.  c, Liver was analyzed on day 6 for p21. n=4 mice.  d-e, SA-β-Gal 
analyses of liver on day 6.  n=3 mice, mean with s.e.m for e. f, Liver was analyzed by 
immunohistochemistry on day 6 and quantified.  n=8 mice; *p<0.005, **p<0.001, ***p<0.0005.   
g, Liver tumor stained for NRas.  One-way ANOVA coupled with Tukey’s post hoc test (b) and 
unpaired two-tailed Student’s t-test for all others.  Scale bars: 10 µm for b and 100 µm for all 
others.  Error bars are s.e.m. 
 
Extended Data Figure 7.  Re-expression of STING in the null liver rescues the SASP. a, 
Illustration of constructs used for hydrodynamic injection.  b, Liver was harvested on day 6 and 
analyzed by immunoblotting.  c, Liver was harvested on day 6 and analyzed by RT-qPCR. n=8 
mice. d, Immunohistochemistry analyses of liver.  Regions with clusters of immune cells are 
indicated with red arrows, and a representative region is shown in inset.  Scale bar: 100 µm.  e, 
Quantification of immune cell clusters and NRas hepatocytes per field.  n=4 mice, *p<0.05, 
**p<0.0005. Unpaired two-tailed Student’s t-test.  Error bars: s.e.m. 
 
Extended Data Figure 8.  Cytoplasmic chromatin promotes proinflammatory responses in 
OIS-evaded and cancer cells.  a,  OIS-evaded IMR90 were analyzed by confocal microscopy.  
b-c, OIS-evaded IMR90 were analyzed by RT-qPCR. n=3, *p<0.05, **p<0.0001, compared to 
sh-NTC.  d-e, Cancer cells were imaged under confocal microscopy; cytoplasmic chromatin 
21 
 
indicated by arrows.  f, Cytoplasmic chromatin were quantified and presented as normalized 
values from four different fields with over 200 cells.  *p<0.05, **p<0.01, ***p<0.005, 
****p<0.0001, compared to control.  g, The four cell lines were stably infected as indicated, 
analyzed by RT-qPCR, and presented as a heatmap.  h, Ten breast cancer cell lines were 
analyzed for cytoplasmic chromatin and pro-inflammatory genes.  Cell lines with the lowest and 
highest 50% of cytoplasmic chromatin were grouped and the cytokine expression levels 
compared.  Error bars: s.e.m. for h and s.d. for all others; one-way ANOVA coupled with 
Tukey’s post hoc test (c and f); unpaired two-tailed Student’s t-test (h).  Scale bars: 10 µm.   
 
Extended Data Figure 9.  CCLE analyses of pro-inflammatory gene expression.  a, Related 
to Fig. 4g, additional genes associated with STING or Lamin B1.  b, Analyses of cGAS with 
pro-inflammatory gene expression profiles.  Samples with the highest 25% and the lowest 25% 
of cGAS expression were selected, grouped, and the numbers of samples are indicated.  c, Lamin 
A/C does not show negative correlation with inflammatory genes.  d, MAVS does not correlate 
with pro-inflammatory gene expression.  Statistical significance is judged by one-sided 
Wilcoxon Rank Sum test.  P values are shown for each comparison.  NS: non-significant 
(p>0.05). See Methods for additional details. 
 
Extended Data Figure 10.  STING associates with pro-inflammatory gene expression in 
human cancers.  Boxplots of TCGA RNA expression profiles in pancreatic adenocarcinoma (a), 
cutaneous melanoma (b), prostate adenocarcinoma (c), and breast adenocarcinoma (d).  In each 
cancer type, samples with the highest 25% and the lowest 25% of STING expression were 
selected, grouped, and the numbers of samples are indicated.  Pro-inflammatory gene expression 
levels were then analyzed between STING high and STING low groups.  Statistical significance 
is judged by one-sided Wilcoxon Rank Sum test.  P values are shown for each comparison.  NS: 
non-significant (p>0.05).  See Methods for additional details. 
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